Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition

被引:51
作者
Chrencik, Jill E.
Brooun, Alexei
Recht, Michael I.
Nicola, George
Davis, Leila K.
Abagyan, Ruben
Widmer, Hans
Pasquale, Elena B.
Kuhn, Peter
机构
[1] Scripps Res Inst, Dept Cellular Biol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[3] Palo Alto Res Ctr, Scripps PARC, Inst Adv Biomed Sci, Palo Alto, CA 94304 USA
[4] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland
[5] Burnham Inst Med Res, La Jolla, CA 92037 USA
关键词
D O I
10.1074/jbc.M706340200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Eph family of receptor tyrosine kinases has been implicated in tumorigenesis as well as pathological forms of angiogenesis. Understanding how to modulate the interaction of Eph receptors with their ephrin ligands is therefore of critical interest for the development of therapeutics to treat cancer. Previous work identified a set of 12-mer peptides that displayed moderate binding affinity but high selectivity for the EphB2 receptor. The SNEW antagonistic peptide inhibited the interaction of EphB2 with ephrinB2, with an IC50 of similar to 15 mu M. To gain a better molecular understanding of how to inhibit Eph/ephrin binding, we determined the crystal structure of the EphB2 receptor in complex with the SNEW peptide to 2.3-angstrom resolution. The peptide binds in the hydrophobic ligand-binding cleft of the EphB2 receptor, thus competing with the ephrin ligand for receptor binding. However, the binding interactions of the SNEW peptide are markedly different from those described for the TNYLRAW peptide, which binds to the ligand-binding cleft of EphB4, indicating a novel mode of antagonism. Nevertheless, we identified a conserved structural motif present in all known receptor/ligand interfaces, which may serve as a scaffold for the development of therapeutic leads. The EphB2-SNEW complex crystallized as a homodimer, and the residues involved in the dimerization interface are similar to those implicated in mediating tetramerization of EphB2-ephrinB2 complexes. The structure of EphB2 in complex with the SNEW peptide reveals novel binding determinants that could serve as starting points in the development of compounds that modulate Eph receptor/ephrin interactions and biological activities.
引用
收藏
页码:36505 / 36513
页数:9
相关论文
共 45 条
[1]   BIASED PROBABILITY MONTE-CARLO CONFORMATIONAL SEARCHES AND ELECTROSTATIC CALCULATIONS FOR PEPTIDES AND PROTEINS [J].
ABAGYAN, R ;
TOTROV, M .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 235 (03) :983-1002
[2]   Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis [J].
Adams, RH ;
Wilkinson, GA ;
Weiss, C ;
Diella, F ;
Gale, NW ;
Deutsch, U ;
Risau, W ;
Klein, R .
GENES & DEVELOPMENT, 1999, 13 (03) :295-306
[3]   Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors [J].
Alazzouzi, H ;
Davalos, V ;
Kokko, A ;
Domingo, E ;
Woerner, SM ;
Wilson, AJ ;
Konrad, L ;
Laiho, P ;
Espín, E ;
Armengol, M ;
Imai, K ;
Yamamoto, H ;
Mariadason, JM ;
Gebert, JF ;
Aaltonen, LA ;
Schwartz, S ;
Arango, D .
CANCER RESEARCH, 2005, 65 (22) :10170-10173
[4]  
[Anonymous], 1997, Cell, V90, P403
[5]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[6]   EphB receptor activity suppresses colorectal cancer progression [J].
Batlle, E ;
Bacani, J ;
Begthel, H ;
Jonkeer, S ;
Gregorieff, A ;
van de Born, M ;
Malats, N ;
Sancho, E ;
Boon, E ;
Pawson, T ;
Gallinger, S ;
Pals, S ;
Clevers, H .
NATURE, 2005, 435 (7045) :1126-1130
[7]   β-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/EphrinB [J].
Batlle, E ;
Henderson, JT ;
Beghtel, H ;
van den Born, MMW ;
Sancho, E ;
Huls, G ;
Meeldijk, J ;
Robertson, J ;
van de Wetering, M ;
Pawson, T ;
Clevers, H .
CELL, 2002, 111 (02) :251-263
[8]   Eph receptor tyrosine kinases in angiogenesis: From development to disease [J].
Brantley-Sieders D.M. ;
Chen J. .
Angiogenesis, 2004, 7 (1) :17-28
[9]  
Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133
[10]   Structure and thermodynamic characterization of the EphB4/ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity [J].
Chrencik, JE ;
Brooun, A ;
Recht, MI ;
Kraus, ML ;
Koolpe, M ;
Kolatkar, AR ;
Bruce, RH ;
Martiny-Baron, G ;
Widmer, H ;
Pasquale, EB ;
Kuhn, P .
STRUCTURE, 2006, 14 (02) :321-330